Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Multi-center, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma

NCT04886765 is registered in ClinicalTrials.gov with AlaMab Therapeutics (Shanghai) Inc. as lead sponsor.

NCT NCT04886765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04886765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Multi-center, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma
Lead sponsor
AlaMab Therapeutics (Shanghai) Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 31, 2021
Completion date
May 31, 2024
Enrollment
238 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

osteosarcoma